Transforming Orthopaedic Revision Surgery
Amotio is redefining orthopaedic revision surgery by developing innovative, patient-specific solutions to remove bone cement safely and efficiently.
Our mission is to improve surgical outcomes, restore mobility, and reduce the burden on healthcare systems worldwide. We believe that every patient deserves a more precise, less invasive revision procedure — and every surgeon deserves tools that make this possible.
A Personalised Approach to Complex Surgery
Our core technology centres around the rapid and effective removal of bone cement, a critical challenge in revision hip, shoulder, and knee surgeries. By combining advanced pre-operative imaging, patient-specific planning, and personalised surgical guide creation and accurate cutting devices, we enable surgeons to work more precisely and confidently.
- • Minimises bone loss
- • Reduces operating time
- • Supports faster recovery
Meeting a Global, Growing Need
The joint replacement market is expanding rapidly with the aging population and increased demand for mobility worldwide.
-
By 2030:
- The global population aged 60+ will reach 1.4 billion
- Over 5 million people 50+ expected to undergo joint replacement each year
- €17.5 billion projected global market for hip, knee, and shoulder replacements
- 50+ age group forms the largest beneficiary of joint implants
-
UK Example:
- 100,000+ primary hip replacements annually (England & Wales)
- 129% increase projected by 2030
-
US & International:
- USA: >200% projected rise (2019–2030)
- Australia: 134% projected rise
- Germany: 29% projected rise (2016–2040)
- OECD: 174 per 100,000 avg. for hip replacement
Despite increasing volumes, revision surgery remains technically demanding, costly, and high-risk. Amotio addresses this unmet need with a unique, clinically validated approach, positioning us for rapid adoption and significant market growth.
Joint Revision Market: A Cycle of Complexity
Revision surgeries are increasing in frequency and risk, yet current solutions remain limited and technically demanding.
within 15 years
within 7 years
within 3 years
- 4–10% of all implants require revision—often multiple times in a lifetime.
- Complexity and risk increase with each surgery.
- Significant cost and resource burden on healthcare systems.
- Unmet need: Current solutions are limited, technically demanding, and lack predictability.
Partnerships & Support
Building with World-Class Partners
We collaborate with leading institutions, surgeons, and healthcare innovators across Europe and the UK. Our partners include UMC Utrecht and Orthopaedic Research UK, as well as support from Welsh Government and Innovate UK. These relationships strengthen our clinical credibility and accelerate our journey to market.
Team & Leadership
Experience That Drives Innovation
Our leadership team combines decades of expertise in healthcare delivery, medical device development, and commercial strategy. CEO and Co-Founder Iestyn Foster brings over 35 years’ experience in surgery, anaesthesia, and MedTech innovation. Supported by expert engineers, clinical advisors, and industry mentors, we are building a company grounded in expertise and driven by patient-centred impact.
Clinical Advisory Board
Board & Governance
Funding & Financials
Backed for Growth
Amotio has secured significant support from leading investors including the Development Bank of Wales, Orthopaedic Research UK, NLC Health Ventures, and key private investors. These funds enable us to advance R&D, complete critical clinical evaluations, and prepare for regulatory approval and market launch.
- Innovate UK
- Welsh Government
- Noord Holland
- Development Bank of Wales
- Orthopaedic Research UK
- NLC Health Ventures
- Key private investors
Milestones & Roadmap
Focused on Delivering Impact
- Technology proof of concept
- Successful prototype development
- Surgeon-led evaluations
- First-in-human studies
- Regulatory submissions
- Scale up manufacturing
- Commercial launch in 2 years
- Expansion across UK & EU
- Global rollout
Regulatory & Quality
Committed to the Highest Clinical and Regulatory Standards
Amotio is progressing towards UKCA, EU MDR and FDA certification, with a comprehensive regulatory strategy in place. Our robust quality management values align with ISO 13485 standards, ensuring that every aspect of our product development prioritises safety, compliance, and clinical efficacy.
ESG & Impact
Improving Lives, Supporting Communities
Beyond transforming surgery, we are committed to making a wider impact. By creating high-value jobs and supporting local communities, we aim to build a sustainable business that benefits patients, healthcare systems, and society. We are driven by the belief that better surgical solutions can restore independence and quality of life for patients worldwide.
News & Updates
Stay Connected
Amotio regularly shares updates on key milestones, partnerships, and industry recognitions. Recent highlights include being named a finalist in the 2025 Allica Bank Great British Entrepreneur Awards and securing additional grant funding to accelerate development.
Interested in Investing in Amotio?
We're actively seeking partners who share our mission to transform orthopaedic care. Reach out to explore opportunities to support our growth.
Contact Us